Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs (COMPARE-AT)
Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study is a single-center, randomized, open-label, active-comparator trial designed to characterize the differential effects of tirzepatide and semaglutide on adipose tissue biology and cardiometabolic remodeling over 12 months in adults with obesity and metabolic syndrome. The trial integrates pharmacologic weight-loss therapy with multimodal phenotyping to quantify changes across body composition, hepatic steatosis, metabolic biomarkers, functional strength, and AI-derived electrophysiologic signatures.
The scientific premise is that incretin-based therapies may produce qualitatively distinct patterns of fat loss, ectopic fat mobilization, and cardiometabolic improvement. Tirzepatide, a dual GIP/GLP-1 receptor agonist, may induce greater reductions in visceral adiposity and hepatic fat compared with GLP-1 receptor agonism alone. This trial is designed to directly compare these mechanistic profiles using harmonized imaging, biochemical, and digital phenotyping platforms.
Participants are randomized 1:1 to tirzepatide or semaglutide using a computer-generated permuted block scheme stratified by sex and baseline BMI category. Both interventions follow standard titration schedules and are paired with structured lifestyle counseling to ensure comparable background care. Study visits occur at baseline, 3, 6, and 12 months, with deep phenotyping at baseline, 6, and 12 months.
The phenotyping framework emphasizes regional adiposity, lean mass preservation, hepatic steatosis, and cardiometabolic risk signatures. Whole-body DXA provides quantification of total and regional fat and lean mass, enabling derivation of fat-to-lean mass loss ratios and redistribution indices. Abdominal MRI with proton density fat fraction (PDFF) quantifies liver fat content and abdominal fat compartments. Functional and behavioral assessments-including grip strength and the Chinese version of the Weight-Related Eating Questionnaire-characterize changes in physical function and eating behavior patterns over time.
Fasting biochemical panels measure glycemic indices, lipid metabolism, inflammation, renal and hepatic function, and cardiometabolic biomarkers. Standard 12-lead ECGs are processed through a validated AI pipeline to generate electrophysiologic risk features (e.g., predicted ASCVD risk, ECG-derived heart age), which serve as exploratory digital biomarkers.
A centralized biobanking program supports mechanistic analyses. Serum, plasma, and PBMCs collected at each deep-phenotyping visit are stored under standardized SOPs for targeted and discovery-based metabolomic, proteomic, epigenetic and transcriptomic analyses. These biospecimens will enable downstream investigation of molecular pathways underlying differential treatment responses.
Together, this integrated platform allows for a comprehensive comparison of tirzepatide and semaglutide across structural, metabolic, functional, and molecular domains, providing mechanistic insight into how incretin-based therapies remodel adipose tissue and cardiometabolic physiology.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Feng-Chih Kuo, M.D., Ph.D.
- Número de telefone: 12687 886-2-87923311
- E-mail: shoummie@hotmail.com
Locais de estudo
-
-
-
Taipei, Taiwan, 114202
- Recrutamento
- Tri-Service General Hospital
-
Contato:
- Feng-Chih Kuo, M.D., Ph.D.
- Número de telefone: 12687 886-2-87923311
- E-mail: shoummie@hotmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age 20-65 years.
- BMI ≥27 kg/m² with metabolic syndrome (ATP III or IDF criteria).
- Stable background medications (antihypertensives, statins, etc.) for ≥3 months.
- Able and willing to provide informed consent and comply with study procedures.
Exclusion Criteria:
- History of diabetes; history of pancreatitis; personal/family history of medullary thyroid carcinoma or MEN2.
- eGFR <30 mL/min/1.73 m², decompensated liver disease, NYHA class III-IV heart failure.
- Recent (<3 months) acute coronary syndrome, stroke, or coronary revascularization.
- Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months.
- Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Tirzepatide arm
starting at 2.5 mg weekly and escalated every month (5.0 mg, 7.5 mg to 10 mg) as tolerated
|
Starting at Tirzepatide 2.5 mg weekly and escalated as tolerated to 10 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.
|
|
Comparador Ativo: Semaglutide arm
starting at 0.25 mg weekly and escalated every month (0.5 mg, 1.0 mg, 1.7 mg to 2.4 mg) as tolerated
|
Starting at Semaglutide 0.25 mg weekly and escalated as tolerated to 2.4 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Percent change in total body weight from baseline to 6 months.
Prazo: Baseline to 6 months
|
Baseline to 6 months
|
|
Total fat to lean mass loss ratio (DXA derived) from baseline to 6 months.
Prazo: Baseline to 6 months
|
Baseline to 6 months
|
|
Change in metabolic syndrome severity Z score from baseline to 6 months.
Prazo: Baseline to 6 months.
|
Baseline to 6 months.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in waist circumference (cm)
Prazo: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in waist-to-hip ratio (unitless ratio)
Prazo: Baseline to 6 months and 12 months.
|
Baseline to 6 months and 12 months.
|
|
|
Change in regional fat mass measured by DXA (grams)
Prazo: Baseline to 6 months and 12 months.
|
Baseline to 6 months and 12 months.
|
|
|
Change in regional lean mass measured by DXA (grams)
Prazo: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in 7-site skinfold thickness (mm)
Prazo: Baseline to 6 months and 12 months.
|
Baseline to 6 months and 12 months.
|
|
|
Change in liver fat content measured by MRI-PDFF (percentage, %PDFF)
Prazo: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in abdominal visceral fat volume (mL)
Prazo: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in abdominal subcutaneous fat volume (mL)
Prazo: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in systolic and diastolic blood pressure (mmHg)
Prazo: Baseline to 6 months and 12 months
|
Baseline to 6 months and 12 months
|
|
|
Change in fasting lipid profile (mg/dL)
Prazo: Baseline to 6 months and 12 months
|
Lipid profile includes total cholesterol, LDL-C, HDL-C and Triglycerides
|
Baseline to 6 months and 12 months
|
|
Change in fasting glucose (mg/dL)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in hsCRP (mg/L)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in insulin sensitivity (HOMA-IR, unitless)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in β-cell function (HOMA-β, percentage, %)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in AI-ECG predicted ASCVD risk score (percentage, %)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in ECG-derived heart age (years)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in AI-ECG diabetes risk index (HbA1c, percentage, %)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in estimated 10-year ASCVD risk (percentage, %)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in bone mineral density (g/cm²)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in serum P1NP (ng/mL)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in serum CTX-1 (ng/mL)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in fasting plasma metabolomics profile (relative abundance units)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in fasting plasma proteomics profile (relative abundance units)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in microRNA expression signatures (normalized expression units)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in RNA-seq transcriptomic signatures (normalized counts, e.g., TPM)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in epigenetic methylation signatures (Methylation, percentage, %)
Prazo: Baseline to 6 and 12 months
|
Baseline to 6 and 12 months
|
|
|
Change in depressive symptoms (scale score)
Prazo: Baseline to 6 and 12 months
|
Instrument: e.g., PHQ-9
|
Baseline to 6 and 12 months
|
|
Change in sleep quality (scale score)
Prazo: Baseline to 6 and 12 months
|
Instrument: e.g., PSQI
|
Baseline to 6 and 12 months
|
|
Change in quality of life (scale score)
Prazo: Baseline to 6 and 12 months
|
Instrument: e.g., EQ-5D or SF-36
|
Baseline to 6 and 12 months
|
|
Change in eating behavior (WREQ-C total and subscale scores)
Prazo: Baseline to 3, 6, and 12 months
|
Baseline to 3, 6, and 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Feng-Chih Kuo, M.D., Ph.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios Nutricionais
- Doenças Metabólicas
- Supernutrição
- Peso corporal
- Distúrbios do Metabolismo da Glicose
- Resistência a insulina
- Hiperinsulinismo
- Excesso de peso
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Obesidade
- Síndrome metabólica
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Receptor peptídeo 1 do tipo glucagon
- Receptores peptídicos semelhantes a glucagon
- Receptores, acoplado à proteína G.
- Receptores, superfície celular
- Proteínas da membrana
- Receptores, hormônio gastrointestinal
- Receptores, peptídeo
- Tirzepatide
- Semaglutide
Outros números de identificação do estudo
- C202505161
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .